Login with Linked

Follow us on

Link Linkedin Youtube

Fabhalta

Fabhalta is an oral capsule that helps treat rare blood and kidney diseases by inhibiting complement factor B. It’s approved for adults with paroxysmal nocturnal hemoglobinuria (PNH), and to reduce proteinuria in complement 3 glomerulopathy (C3G) and IgA nephropathy.

Molecule Details :

  • Molecule Name :

    Iptacopan

  • Innovator :

    NOVARTIS PHARMACEUTICALS CORP

  • Approval Date :

    05-Dec-23

  • NCE-1 Date :

    05-Dec-27

  • NCE Date :

    05-Dec-28

  • Dosage Form :

    Capsule

  • Strength :

    200mg

  • Therapeutic Category :

    Immunomodulators

  • Revenue ($M) :

    129

Year-wise Projected Sales ($M) :

  • 2025 :

    487

  • 2026 :

    985

  • 2027 :

    1,493

  • 2028 :

    1,945

  • 2029 :

    2,364

  • 2030 :

    2,765

  • 2031 :

    3,124
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.
Request a Quote

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Schedule a Call With Us
Login with Linked

Follow us on

Linkedin Youtube Link

Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?

Not Now
Logout
Need your comparator insight?